ChromaDex Corporation

NasdaqCM CDXC

ChromaDex Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 55.76%

ChromaDex Corporation Gross Profit Margin is 55.76% for the Trailing 12 Months (TTM) ending September 30, 2024, a -6.76% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • ChromaDex Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 59.80%, a -1.19% change year over year.
  • ChromaDex Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 60.52%, a -1.55% change year over year.
  • ChromaDex Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 61.48%, a 4.99% change year over year.
  • ChromaDex Corporation Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 58.55%, a 7.54% change year over year.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
Loading...
NasdaqCM: CDXC

ChromaDex Corporation

CEO Mr. Robert N. Fried
IPO Date June 25, 2008
Location United States
Headquarters 10900 Wilshire Boulevard
Employees 106
Sector Health Care
Industries
Description

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Similar companies

MNOV

MediciNova, Inc.

USD 1.91

-4.02%

RZLT

Rezolute, Inc.

USD 4.72

-0.63%

JANX

Janux Therapeutics, Inc.

USD 45.35

0.64%

XCUR

Exicure, Inc.

USD 8.62

9.11%

ADAG

Adagene Inc.

USD 1.80

1.12%

MLYS

Mineralys Therapeutics, Inc.

USD 9.12

-2.56%

ANTX

AN2 Therapeutics, Inc.

USD 1.22

-3.17%

IPSC

Century Therapeutics, Inc.

USD 0.94

-3.60%

AVTE

Aerovate Therapeutics, Inc.

USD 2.47

-1.20%

ACRV

Acrivon Therapeutics, Inc. Common Stock

USD 5.56

0.91%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

NKTX

Nkarta, Inc.

USD 2.21

-4.33%

KZR

Kezar Life Sciences, Inc.

USD 6.21

-1.43%

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

StockViz Staff

January 15, 2025

Any question? Send us an email